Newcastle Under Lyme

Researchers are studying the effects of ensifentrine inhalation suspension compared to placebo in adults with non-cystic fibrosis bronchiectasis (NCFBE). The goal is to evaluate how ensifentrine affects the rate of lung flare-ups, symptoms, and quality of life in this condition. This Phase II trial is randomized, double-blind, and placebo-controlled to ensure unbiased assessment of ensifentrine's safety and effectiveness alongside standard care. Participants will be randomly assigned to receive either 3 mg of nebulized ensifentrine suspension or a placebo, both administered twice daily using a standard jet nebulizer. The treatment period will last at least 24 weeks and may continue up to 52 weeks, with neither the participants nor the study staff knowing which treatment is given. This setup helps compare ensifentrine's effects directly against placebo over an extended period. During the study, participants will attend regular visits for lung function tests, symptom assessments, and quality of life evaluations. Researchers will monitor lung flare-ups defined by the need for antibiotics or antivirals over approximately 52 weeks. Safety will be closely observed, and participants' ability to use the nebulizer and provide sputum samples will be assessed. This thorough monitoring aims to gather detailed data on ensifentrine's impact on NCFBE symptoms and flare-up frequency.